Asunto(s)
Productos Biológicos/uso terapéutico , COVID-19/epidemiología , Psoriasis/tratamiento farmacológico , Adulto , Comorbilidad , Femenino , Francia/epidemiología , Humanos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , SARS-CoV-2 , Encuestas y Cuestionarios , Brote de los SíntomasRESUMEN
We investigated the plasma levels of PMPs in patients with 45 stage III and 45 stage IV melanoma. PMPs were characterised by flow cytometry and their thrombogenic activity. We also investigated the link between PMPs circulating levels and tumor burden. The circulating levels of PMPs were significantly higher in stage IV (8500 µL-1 ) than in patients with stage III (2041 µL-1 ) melanoma (P=.0001). We calculated a highly specific (93.3%) and predictive (91.7%) cut-off value (5311 µL-1 ) allowing the distinction between high-risk stage III and metastatic stage IV melanoma. The thrombogenic activity of PMPs was significantly higher in patients with stage IV melanoma (clotting time: 40.7 second vs 65 second, P=.0001). There was no significant association between the radiological tumoral syndrome and the plasma level of PMPs. Our data suggest the role of PMPs in metastatic progression of melanoma.
